Abstract
Acute decompensated heart failure (ADHF) with associated volume overload is the most common cause of hospitalization in heart failure patients. When accompanied by worsening renal function, it is described as a cardiorenal syndrome and is a therapeutic challenge. Initial treatment commonly encompasses intravenous diuretics however, suboptimal results and high rehospitalization rates have led experts to search for alternative therapeutic strategies. Recent technological advances in extracorporeal therapies have made ultrafiltration a feasible option for treatment of hypervolemia in ADHF. Recent large randomized trials have compared the efficacy and safety of ultrafiltration with diuretics. Additionally, the benefits of novel pharmacologic approaches, including combining hypertonic saline with diuretics, have recently been studied. The aim of this review is to discuss the developments in both pharmacologic and extracorporeal methods for treating hypervolemia in ADHF and acute cardiorenal syndrome.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Kellum JA, et al. The 3rd International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). Int J Artif Organs. 2005;28(5):441–4.
Gheorghiade M, et al. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112(25):3958–68.
Thom T, et al. Heart disease and stroke statistics–2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113(6):e85–e151.
Adams Jr KF, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149(2):209–16.
Heywood JT. The cardiorenal syndrome: lessons from the ADHERE database and treatment options. Heart Fail Rev. 2004;9(3):195–201.
Metra M, et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail. 2012;5(1):54–62.
Hunt SA, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):e391–479.
Felker GM, Mentz RJ. Diuretics and ultrafiltration in acute decompensated heart failure. J Am Coll Cardiol. 2012;59(24):2145–53.
• Schrier RW. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol. 2006;47(1):1–8. An excellent summary of the relationships between cardiac and renal functions.
Schrier RW, et al. Therapy of heart failure. Kidney Int. 2000;57(4):1418–25.
Faris R, et al. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol. 2002;82(2):149–58.
Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2001;96(3–4):132–43.
Francis GS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82(5):1724–9.
Domanski M, et al. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 2003;42(4):705–8.
Abdallah JG, et al. Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(−)-cotransporter abundance: role of aldosterone. J Am Soc Nephrol. 2001;12(7):1335–41.
Hirsch AT, et al. Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure. Am J Cardiol. 1990;66(11):22D–30D. discussion 30D-32D.
Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345(23):1689–97.
McCurley JM, et al. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol. 2004;44(6):1301–7.
He XR, et al. Effects of furosemide and verapamil on the NaCl dependency of macula densa-mediated renin secretion. Hypertension. 1995;26(1):137–42.
Modena B, et al. Furosemide stimulates renin expression in the kidneys of salt-supplemented rats. Pflugers Arch. 1993;424(5–6):403–9.
Almeshari K, et al. A volume-independent component to postdiuretic sodium retention in humans. J Am Soc Nephrol. 1993;3(12):1878–83.
De Bruyne LK. Mechanisms and management of diuretic resistance in congestive heart failure. Postgrad Med J. 2003;79(931):268–71.
Cooper HA, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999;100(12):1311–5.
• Felker GM, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797–805. DOSE study, largest randomized controlled trial examining diuretic therapy for ADHF.
Butler J, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004;147(2):331–8.
Felker GM, O'Connor CM, Braunwald E. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail. 2009;2(1):56–62.
Aronson D, Burger AJ. The relationship between transient and persistent worsening renal function and mortality in patients with acute decompensated heart failure. J Card Fail. 2010;16(7):541–7.
Testani JM, et al. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010;122(3):265–72.
• Paterna S, et al. Short-term effects of hypertonic saline solution in acute heart failure and long-term effects of a moderate sodium restriction in patients with compensated heart failure with New York Heart Association class III (Class C) (SMAC-HF Study). Am J Med Sci. 2011;342(1):27–37. Largest to date study of the use of Hypertonic Saline Solution in ADHF.
Kolff WJ, Leonards JR. Reduction of otherwise intractable edema by dialysis or filtration. Cleve Clin Q. 1954;21(2):61–71.
Ali SS, O.C., Sobotka P. Enhanced sodium extraction with ultrafiltration compared to intravenous diuretics. Heart Failure Society of America 2006 Scientific Meeting; 2006.
Fauchald P. Effects of ultrafiltration on body fluid volumes and transcapillary colloid osmotic gradient in hemodialysis patients. Contrib Nephrol. 1989;74:170–5.
Marenzi G, et al. Interrelation of humoral factors, hemodynamics, and fluid and salt metabolism in congestive heart failure: effects of extracorporeal ultrafiltration. Am J Med. 1993;94(1):49–56.
Agostoni P, et al. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. Am J Med. 1994;96(3):191–9.
Costanzo MR, et al. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol. 2005;46(11):2047–51.
Bart BA, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol. 2005;46(11):2043–6.
•• Costanzo MR, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49(6):675–83. UNLOAD trial, the largest randomized controlled trial to date comparing diuretic therapy with ultrafiltration for ADHF.
•• Bart BA, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367(24):2296–304. CARRESS-HF trial, the most recent randomized controlled trial comparing diuretic therapy with ultrafiltration for ADHF with type 1 cardiorenal syndrome.
Aspromonte N, et al. Role of bioimpedance vectorial analysis in cardio-renal syndromes. Semin Nephrol. 2012;32(1):93–9.
Disclosure
No potential conflicts of interest relevant to this article were reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Prosek, J., Agarwal, A. & Parikh, S.V. Cardiorenal Syndrome and the Role of Ultrafiltration in Heart Failure. Curr Heart Fail Rep 10, 81–88 (2013). https://doi.org/10.1007/s11897-012-0129-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11897-012-0129-1